IGF1 and neoplasm: Preclinical studies found that metformin reduces insulin and IGF-1 level in serum and stables blood glucose level through AMPK pathway and thus reverses the tumor promoting effect driven by hyperinsulinemia and hyperglycemia [10, 12–15].